Abbott’s Neuropathic Pain Blocker Cleared for Marketing

The FDA and EU have both cleared Abbott’s DRG Invisible Trial system for marketing, a device designed to help people suffering from neuropathic pain.

The device targets the dorsal root ganglion (DRG), a nerve structure near the spinal cord that transmits chronic pain to the nervous system.

By transmitting electrical pulses through a thin wire placed in the spinal column near the DRG, the system blocks pain signals from reaching the nervous system.